Integrated Delivery Networks (IDNs)
Trends Driving Healthcare Delivery and Biopharma Opportunities for Customer Engagement
Pharmaceutical companies that are seeking ways to engage and partner with integrated delivery networks must understand this: IDNs are evolving in ways that have a profound effect on how healthcare is managed, what care paths are followed and which populations are carved out for special attention.
TGaS Advisors, a division of Trinity Life Sciences, conducted 15 in-depth interviews with key decision-makers from advanced healthcare systems in the U.S. to understand their perspectives on what is driving IDNs and what they are seeking in partnerships. To complement these results, 12 market access leaders from pharmaceutical companies were interviewed to gain their perspectives about their existing partnerships and the challenges they face while collaborating with IDNs.
What was learned is that the old rules do not apply. IDNs do not want a sales pitch in any way, shape or form. They want partners who truly understand their goals in managing patients with chronic illness, they need analytics to make that happen and they are open to risk-based contracts.
This has been heard a lot before. The Quadruple Aim of better care for individuals, better health for populations and lower per-capita costs has been discussed for decades, but this time the most advanced IDNs have the benefit of experience and access to better technology. They are looking for partnerships with pharmaceutical companies that help them achieve that Quadruple Aim.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Briefs
2025 Annual State of Learning & Development in Life Sciences
Through the 2020s, life sciences leaders have dealt with one challenge after another. The shock of the COVID-19 pandemic. Sticky inflation. Return-to-office mandates. The intense pressure to perform in the face of disruptive challenges has proven constant. For commercial learning and development, also known as commercial L&D, this has presented new roadblocks and innovations alike, […]
Read More
Briefs
Leading the Evolution: Navigating AI and Pharma Market Trends
How are Commercial, Medical and Market Access organizations evolving to develop capabilities and accelerate innovation in 2025 and beyond? Executive leaders are focused on making informed organizational decisions to propel the evolution of capabilities in this rapidly changing global economy. As you strategize to optimize structure, talent and capabilities to excel in the future, this Advisory Brief brings you critical insights gleaned from the recent TGaS Advisors’ 2025 Spring Summit.
Read More
Blog
Is Medical Omnichannel Poised for Growth?
79% of respondents are predicting an increase in spend in Omnichannel capabilities for Medical Affairs in 2025, according to a recent TGaS survey fielded in September 2024.* This predicted increase for Medical Omnichannel indicates that there is a real need to find ways to inform, educate and engage HCPs beyond the traditional in-person channel. What […]
Read More